Levodopa-induced dyskinesias and substantia nigra dopamine D3 receptor availability in Parkinson’s disease
Objective: To investigate with PET and the radioligand [11C]PHNO whether levodopa-induced dyskinesias in Parkinson disease (PD) are associated with dopamine-D3 receptor (D3R) overexpression in substantia nigra…Neuroimaging Extra-Striatal D2 Receptors in Parkinson’s Disease with Rapid Eye Movement Sleep Behaviour Disorder
Objective: Our aim was to characterize the extra-striatal dopamine in Parkinson’s disease (PD) with and without rapid eye movement sleep behaviour disorder (RBD) using in…The influence of ANNK1/DRD2 haplotypes on the onset of complications of long-term levodopa therapy in Parkinson’s disease
Objective: To investigate an influence of selected polymorphisms in DRD2 and ANKK1 genes on the occurrence of complications of long-term levodopa therapy in Serbian PD…Dopamine receptor variants alter outcomes with levodopa in early-stage Parkinson’s disease
Objective: To examine if specific single nucleotide polymorphisms (SNPs) in the genes for dopamine receptors 2 and 3 (DRD2, DRD3) correlate with worse outcomes within specific…Efficacy, Safety and Tolerability of Tavapadon in Subjects With Early Stage Parkinson’s Disease
Objective: To evaluate the efficacy and safety of tavapadon (formerly known as PF-06649751) in subjects with early stage Parkinson’s disease. Background: Tavapadon is a potent,…Treatment monitoring using objective and frequent digital testing in the D1PAM (LY3154207) phase 1B Parkinson’s disease clinical trial
Objective: This study evaluates the feasibility, reliability, and validity of smartphone app-based testing in patients with Parkinson’s disease (PD) in the D1PAM (D1 positive allosteric…Preclinical profile of dopamine D1PAM: A novel mechanism in clinical development for Lewy Body dementia
Objective: Introduce the mechanism of action for dopamine D1 positive allosteric modulator (D1PAM) as a new target for neuropsychiatric disorders. Describe the preclinical profile of…Evidence of survival and integration of implanted autologous peripheral nerve graft in substantia nigra in a patient with Parkinson’s disease
Objective: We report a patient with Parkinson’s disease (PD) who underwent deep brain stimulation (DBS) simultaneously with peripheral nerve graft in substantia nigra (SN) and the…Modeling of Parkinson’s disease by damaging dopaminergic neurons
Objective: Analysis of the simulation of Parkinson's disease in rats using 6-OHDA.Analysis of the simulation of Parkinson's disease in rats using 6-OHDA. Background: The mechanism…Pramipexole regulates the depressive-like symptom through dopamine D3 not dopamine D2 receptor in a mouse model of Parkinson’s disease
Objective: The aim of this study is to understand if the antidepressant effect of pramipexole is mediated by D2R or D3R in a mouse model…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.